自主AI如何重塑生物制药运营：从决策辅助工具转向自主执行系统

News|Articles|October 26, 2026

Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical trials, commercial launch and regulatory work.

The biopharmaceutical industry stands at an inflection point. For years, the sector has leveraged artificial intelligence (AI) as a sophisticated analytical tool and digital assistant capable of parsing vast datasets, identifying molecular targets and optimizing clinical trial recruitment.¹ However, the landscape has fundamentally shifted. We have entered the "agentic era," a period defined not by AI that merely informs human decision-making, but by autonomous systems that independently execute complex, multi-step workflows.

This transition from smart tools to autonomous digital colleagues represents a paradigm shift in how biopharmaceutical companies operate. Unlike traditional machine learning models or dashboard-centric decision support systems that require constant human prompting, agentic AI operates with genuine autonomy. These systems are engineered to initiate and complete tasks, such as generating comprehensive study protocols, simulating diverse trial arms, drafting detailed regulatory submissions and triggering necessary supply chain adjustments without direct human initiation.

As industry grapples with rising research and development costs, intensifying competition and the perennial challenge of bringing life-saving therapies to market efficiently, adopting agentic AI is no longer a futuristic concept but a present-day imperative. By 2027, AI agents are projected to augment or automate 50% of all business decisions for decision intelligence.² For life sciences professionals, understanding and integrating these autonomous systems is essential to maintain competitive advantage and drive the next wave of medical innovation.

The Evolution of AI in Biopharma: From Analytics to Agency

The traditional biopharmaceutical lifecycle, spanning initial discovery to commercialization, is notoriously lengthy and resource-intensive, often taking up to 15 years and costing billions of dollars. Historically, AI interventions in this process were siloed and task-specific. A model might predict a compound's binding affinity, but a human scientist still needed to interpret the result, design the next experiment and manually input data into the next system.

Agentic AI transcends these limitations. These intelligent agents exhibit adaptive learning capabilities, maintain persistent memory of past interactions, possess contextual awareness and seamlessly link tasks across disparate departments and geographical locations. They can reason, plan and execute actions to achieve a defined goal.

Consider a scenario where an intelligent agent autonomously detects a critical shift in regulatory policy. The agent proactively updates the relevant target product profile, meticulously simulates the potential impact of this change on key trial endpoints and immediately alerts the relevant clinical team — all before a human analyst even notices the policy update. This transcends mere operational support, representing proactive strategic alignment driven by autonomous intelligence.

The economic implications of this shift are profound. The global AI in pharmaceutical market is projected to grow from $6.63 billion in 2025 to $8.54 billion in 2026.³ Furthermore, the generative AI market in healthcare is expected to expand at an 85% compound annual growth rate, reaching $22 billion by 2027.⁴

Redefining the Value Chain

Accelerating Discovery and Preclinical Development

In the drug discovery phase, intelligent agents propose novel drug candidates through sophisticated generative molecular design. They efficiently cross-reference vast repositories of public and proprietary datasets and rapidly simulate critical absorption, distribution, metabolism, excretion and toxicity properties at unprecedented speeds.¹

This capability is particularly relevant given recent regulatory shifts. In April 2025, the FDA announced a landmark plan to phase out mandatory animal testing requirements for monoclonal antibodies and other drugs, establishing a roadmap to replace in vivo studies with more precise, human-relevant science.⁵ By April 2026, the FDA reported achieving its key first-year goals in this initiative, noting that historically, more than 90% of drugs that clear animal studies fail to receive FDA approval due to safety or efficacy issues in human trials.⁵

This regulatory pivot creates fertile ground for the widespread adoption of agentic systems. AI agents can conduct predictive safety and efficacy analyses using novel approach methodologies, such as advanced in vitro systems and computational modeling, significantly reducing reliance on animal testing while improving the prediction of drug effects in humans. Notably, the FDA has now qualified its first artificial intelligence-based drug development tool, demonstrating the utility of leveraging innovative in silico models to support regulatory decision-making.⁵

Revolutionizing Clinical Trials

Clinical trials represent one of the most significant bottlenecks in drug development. Agentic systems are increasingly shaping this phase by optimizing patient eligibility criteria, simulating complex patient flows and generating adaptive trial designs in silico.⁶ AI agents can proactively predict potential patient dropout risks and issue real-time alerts to study teams, helping prevent protocol deviations.

For example, specialized clinical research associate (CRA) agents can autonomously identify and prioritize site risks, generate pre-visit summaries and provide actionable recommendations. Industry data indicate that such agents can manage up to 90% of the tactical and administrative work typically managed by human CRAs, freeing clinical teams to focus on strategic oversight.⁷ Furthermore, trial master file agents automate the high-volume work of organizing and filing trial documents. By automating document intake, intelligent classification and metadata extraction, these systems can reduce time spent per document by up to 60%, ensuring continuous inspection readiness and regulatory compliance.⁷

Transforming Regulatory and Commercial Operations

Regulatory functions are undergoing a profound transformation. AI agents, trained on decades of regulatory submissions and reviewer feedback, can now draft comprehensive common technical document modules and prepare detailed briefing materials for advisory committee meetings. One leading global pharmaceutical company partnered with a consultancy to deploy a multi-agent AI system for medical writing. This system integrated internal content platforms with external scientific databases, drastically cutting the time required to produce a first draft of a clinical trial protocol — a process that previously took up to six months — while maintaining rigorous scientific and regulatory standards.⁴

In the commercial and operational domains, AI systems continuously monitor real-time formulary changes, analyze competitor strategies and gauge key opinion leader sentiment to inform agile launch strategies. Concurrently, intelligent manufacturing agents respond dynamically to biologic stability data, optimize complex cold chain logistics, and orchestrate intricate facility-level workflows with minimal direct human oversight.

A Real-World Blueprint: The Moderna-OpenAI Partnership

The theoretical promise of agentic AI is compelling, but its practical application requires strategic vision and rigorous execution. A compelling real-world example of this transformative shift is the strategic partnership between Moderna and OpenAI, which provides a blueprint for enterprise-wide AI adoption.⁸

Moderna possessed a mature, cloud-native digital infrastructure that primed it for rapid AI integration. However, the success of their AI initiative was driven not just by technology, but by a concerted focus on culture and up-skilling. CEO Stéphane Bancel articulated a clear vision: AI was not merely an IT project, but a mission-critical enabler designed to allow a few thousand employees to achieve the impact of 100,000.⁸

To realize this vision, Moderna established an ambitious target: 100% of eligible employees proficient in generative AI within six months. This broad up-skilling was paired with an internal prompt contest to identify power users, creating a network of "Generative AI Champions" to drive adoption across teams.⁸

When ChatGPT Enterprise was deployed company-wide, the engagement was unprecedented. Within just two months, Moderna employees created 750 custom GPTs tailored to specific workflows. Remarkably, 40% of active users built their own GPTs and average user engagement reached approximately 120 conversations per week.⁸ These agents augment cognitive functions across legal, medical, manufacturing and commercial teams. For instance, a "Dose ID" GPT accelerates vaccine dose selection by analyzing complex clinical data, while a "Contract Companion" GPT rapidly summarizes legal agreements. To support this integration, Moderna restructured its organization, merging Human Resources and IT into a unified "People & Digital" department — a structural acknowledgment that managing human and artificial intelligence must be deeply integrated.⁸

Navigating Challenges: Governance and Guardrails

Despite the considerable promise of agentic AI, its widespread adoption is not without significant challenges. Existing data silos, outdated legacy IT infrastructure, evolving regulatory uncertainties and inherent institutional resistance represent substantial barriers. The fundamental value of agentic AI lies in its capacity to break down traditional silos by operating seamlessly across diverse disciplines and integrating disparate knowledge domains in ways that human teams often struggle to achieve.⁹ However, this requires a robust underlying data architecture; generative AI cannot deliver results without a proper data foundation.

Furthermore, deploying autonomous systems in a highly regulated, high-stakes industry requires stringent ethical and operational guardrails. Effective deployment requires access to high-quality, meticulously curated training data, robust explainability protocols to understand decision-making processes, and continuous validation strategies to maintain trust and reliability.

Biopharmaceutical companies must proactively develop governance frameworks specifically designed to oversee machine-driven actions. This includes establishing comprehensive AI assurance protocols with clear guidelines for data quality, model validation and continuous monitoring. Organizations must maintain detailed audit trails of autonomous decisions to satisfy regulatory scrutiny, while implementing fail-safe escalation pathways that ensure clear mechanisms for human intervention when an agent encounters ambiguity or high-risk scenarios. Cross-disciplinary AI review boards — comprising data scientists, clinicians, ethicists and legal experts — are essential for evaluating AI deployments and ensuring autonomous systems operate within acceptable risk parameters.

Without deliberate and comprehensive governance frameworks, the inherent risks of automation bias, opaque algorithmic logic chains and systemic errors within critical processes will inevitably grow. The industry must recognize that governance is not a constraint on innovation but an enabler of sustainable, trustworthy AI adoption.

The Imperative for Agentic Leadership

The successful navigation of this agentic era requires a new breed of leadership within biopharmaceutical organizations. As autonomous systems increasingly execute critical decisions, organizational leadership must evolve its focus from granular micromanagement to defining overarching strategic goals, ensuring robust ethical governance, and aligning machine-driven outputs with core mission-driven objectives.

This evolution extends beyond the traditional role of chief digital officers to the emergence of chief agent officers, strategic leaders specifically tasked with aligning autonomous AI systems with enterprise strategy and ensuring adherence to the highest ethical standards. These leaders must possess a unique blend of deep technical fluency and a strong commitment to human-centered oversight, ensuring that AI acts not only with speed and efficiency but also with wisdom, transparency and a clear alignment with patient well-being.

The future of the biopharmaceutical industry belongs to those forward-thinking organizations that can effectively orchestrate the combined power of human and machine intelligence at scale. The next major therapeutic breakthrough may very well originate not solely from a traditional laboratory bench, but from an intelligent AI agent autonomously simulating billions of potential molecular permutations in silico. Those who hesitate to embrace this paradigm shift risk falling behind in one of the world's most competitive industries. Companies that strategically deploy agentic systems are not simply operating faster; they are fundamentally becoming more intelligent, agile and responsive organizations. When sophisticated AI acts intelligently and ethically on behalf of scientific progress, efficiency and patients, the benefits will accrue to us all.

Partha Anbil is life sciences industry advisor at MIT Sloan CDO. Satish Tadikonda is a senior lecturer in the Entrepreneurial Management Unit at Harvard Business School.

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

References

Zhang K, Yang X, Wang Y, et al. Artificial intelligence in drug development. Nature Medicine. 2025;31:45-59. Accessed October 26, 2026. doi:10.1038/s41591-024-03434-4
Exploring the value of agentic AI in life sciences. IQVIA. January 2026. Accessed October 26, 2026. https://www.iqvia.com/blogs/2026/01/exploring-the-value-of-agentic-ai-in-life-sciences
AI in pharma and biotech market size, share and growth. Fortune Business Insights. 2026. Accessed October 26, 2026. https://www.fortunebusinessinsights.com/ai-in-pharma-and-biotech-market-110287
Agentic AI in biopharma: Game-changing efficiency. Boston Consulting Group. 2025. Accessed October 26, 2026. https://www.bcg.com/publications/2025/agentic-ai-in-biopharma-game-changing-efficiency
FDA achieves Year 1 goals in reducing animal testing in drug development. U.S. Food and Drug Administration. 2026. Accessed October 26, 2026. https://www.fda.gov/news-events/press-announcements/fda-achieves-year-1-goals-reducing-animal-testing-drug-development
Lakhan SE. The agentic era: why biopharma must embrace artificial intelligence that acts, not just informs. Cureus. 2025;17(5):e83390. Accessed October 26, 2026. doi:10.7759/cureus.83390
How agentic AI is transforming life sciences discovery and operations. Medable. 2025. Accessed October 26, 2026. https://www.medable.com/knowledge-center/how-agentic-ai-is-transforming-life-sciences-discovery-and-operations
Moderna and OpenAI partner to accelerate the development of life-saving treatments. OpenAI. 2025. Accessed October 26, 2026. https://openai.com/index/moderna/
Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine. 2019;25:44-56. Accessed October 26, 2026. doi:10.1038/s41591-018-0300-7